HER-2 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome

Ressel, Lorenzo; Puleio, Roberto; Loria, Guido Ruggero; Vannozzi, Iacopo; Millanta, Francesca; Caracappa, Santo; Poli, Alessandro

doi:10.1016/j.rvsc.2012.09.016

Cited by 49 publications

(61 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, some authors observed that HER-2 over-expression in MMT was positively associated with indicators of poor prognosis in the bitch (Martin de las Mulas et al, 2003;Dutra et al, 2004). However, Ressel et al, (2013) found that bitches with HER-2 over-expressing carcinomas did not present a poorer prognosis than those with HER-2-non-over-expressing tumors. Considering these controversial results, additional studies are required in order to investigate the significance of HER-2 over-expression in MMT.…”

Section: Prognosismentioning

confidence: 99%

Canine Mammary Tumors: Risk Factors, Prognosis and Treatments

2016

View full text Add to dashboard Cite

Mammary tumors are the most common neoplasm in the female dog, with a median age of appearance between 9 and 11 years. They may appear as single or multiple nodules, and posterior mammary glands are more frequently affected than anterior glands. Both benign and malignant tumors may occur in the dog, and according to histological criteria, approximately 50% of the tumors are malignant. Mammary gland tumors tend to be heterogeneous in their pathological characteristics and clinical behavior. Different hormones and growth factors play a key role in the development of this neoplasm, however, the mechanism by which they influence tumor growth and their possible prognostic value are still under study. Besides, new therapeutic options for each particular tumor type are being developed. The aim of this article is to review pathological, prognostic and therapeutic aspects of canine mammary neoplasms.

show abstract

Section: Prognosismentioning

confidence: 99%

Canine Mammary Tumors: Risk Factors, Prognosis and Treatments

2016

View full text Add to dashboard Cite

show abstract

“…Even though the expression of HER2 has been largely investigated in HBC, only few studies examined HER2 expression in CMT, mostly at the protein level and using the HercepTest ™ scoring system and the related Dako policlonal antibody [12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?

Burrai

Tanca²,

Miglio

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

Canine mammary tumors (CMTs) share many features with human breast cancer (HBC), specifically concerning cancer-related pathways. Although the human epidermal growth factor receptor 2 (HER2) plays a significant role as a therapeutic and prognostic biomarker in HBC, its relevance in the pathogenesis and prognosis of CMT is still controversial. The aim of this study was to investigate HER2 expression in canine mammary hyperplasic and neoplastic tissues as well as to evaluate the specificity of the most commonly used polyclonal anti HER2 antibody by multiple molecular approaches. HER2 protein and RNA expression were determined by immunohistochemistry (IHC) and by quantitative real-time (qRT) PCR. A strong cell membrane associated with non-specific cytoplasmic staining was observed in 22% of carcinomas by IHC. Adenomas and carcinomas exhibited a significantly higher HER2 mRNA expression when compared to normal mammary glands, although no significant difference between benign and malignant tumors was noticed by qRT-PCR. The IHC results suggest a lack of specificity of the FDA-approved antibody in CMT samples as further demonstrated by Western immunoblotting (WB) and reverse phase protein arrays (RPPA). Furthemore, HER2 was not detected by mass spectrometry (MS) in a protein-expressing carcinoma at the IHC investigation. This study highlights that caution needs to be used when trying to translate from human to veterinary medicine information concerning cancer-related biomarkers and pathways. Further investigations are necessary to carefully assess the diagnostic and biological role specifically exerted by HER2 in CMTs and the use of canine mammary tumors as a model of HER2 over-expressing breast cancer.

show abstract

“…The conducted research confirmed EGFR overexpression in cases of milk gland cancer in dogs -it oscillated between 16 and 29% but was not correlated with the mitotic activity of the tumour or patient survival (24). The results are contrary to those reported by Dutr, who observed that EGF receptor expression was related to milk gland carcinogenesis and correlated with the indicators of histological malignancy and negative prognoses (25).…”

Section: Discussionmentioning

confidence: 67%

“…It was confirmed that the use of antibodies against EGFR receptors may inhibit or even entirely arrest tumour growth (24).…”

Section: Discussionmentioning

confidence: 91%

Elevated EGF Levels in the Blood Serum of Dogs with Periodontal Diseases and Oral Tumours

Sobczyńska-Rak

Żylińska

Polkowska

et al. 2018

View full text Add to dashboard Cite

show abstract

HER-2 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome

Cited by 49 publications

References 25 publications

Canine Mammary Tumors: Risk Factors, Prognosis and Treatments

Canine Mammary Tumors: Risk Factors, Prognosis and Treatments

Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?

Elevated EGF Levels in the Blood Serum of Dogs with Periodontal Diseases and Oral Tumours

Contact Info

Product

Resources

About